A Randomised, Multicentre, Investigator-Blind, Parallel-Group Trial to Evaluate the Efficacy and Safety of MC2-01 Cream Compared to Vehicle and Active Comparator in Subjects With Mild-to-Moderate Psoriasis Vulgaris
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 09 May 2018
At a glance
- Drugs Betamethasone-dipropionate/calcipotriol (Primary)
- Indications Plaque psoriasis
- Focus Registrational; Therapeutic Use
- Sponsors MC2 Therapeutics
- 01 May 2018 Status changed from recruiting to active, no longer recruiting.
- 16 Oct 2017 New trial record
- 11 Oct 2017 According to a MC2 Therapeutics media release, topline results are expected in Q3 2018 and will constitute the basis for an NDA submission.